1.65
-0.035(-2.08%)
Currency In USD
| Previous Close | 1.68 |
| Open | 1.69 |
| Day High | 1.72 |
| Day Low | 1.64 |
| 52-Week High | 2.43 |
| 52-Week Low | 0.66 |
| Volume | 214,178 |
| Average Volume | 1.23M |
| Market Cap | 191.19M |
| PE | 3.1 |
| EPS | 0.53 |
| Moving Average 50 Days | 1.52 |
| Moving Average 200 Days | 1.1 |
| Change | -0.04 |
If you invested $1000 in Coherus BioSciences, Inc. (CHRS) 10 years ago, it would be worth $57.1 as of November 03, 2025 at a share price of $1.645. Whereas If you bought $1000 worth of Coherus BioSciences, Inc. (CHRS) shares 5 years ago, it would be worth $96.31 as of November 03, 2025 at a share price of $1.645.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Ea
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire Inc.
Oct 03, 2025 1:05 PM GMT
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CH
Coherus Oncology to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Sep 03, 2025 12:30 PM GMT
REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences: Baird 2025 Global Healthcare Conference in N